Company / R&D Expense
Insight Molecular Diagnostics Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$9.8M
FY2025
5-year range
$5.0M / $9.8M
FY2021-FY2025
Trend
+5.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 3 consecutive years, from $5M in FY2022 to $10M in FY2025.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +7.7%.
Improved from $7M to $10M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +25.0%
- 5-Year CAGR
- +7.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Insight Molecular Diagnostics Inc.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +7.7%, indicating consistent growth.
- In FY2025, r&d expense increased 5.9% year-over-year.
- Lowest r&d expense in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.8M | +5.9% |
| FY2024 | $9.3M | +27.3% |
| FY2023 | $7.3M | +45.0% |
| FY2022 | $5.0M | -48.6% |
| FY2021 | $9.8M | +44.2% |
| FY2020 | $6.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026